Bayer – Pulmonary arterial hypertension

Access Program Information

<p>The aim of the study is to assess safety, tolerability and clinical effects of different doses of <strong>Riociguat</strong> in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and who are not satisfactorily treated and cannot participate in any other CTEPH trial. In the US the study runs as an Expanded Access program under 21 CFR 312.320.</p>